Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Research and Innovation Action · Running

SENSOPAD Sensing ENdometriosiS On Portable Auxiliary Devices

Coordinator
Ethnicon Metsovion Polytechnion, Greece
Runs
1 September 2024 to 31 August 2028
Status
Running
EU funding
€6.9m
Total cost
—
Partners
14 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101130516

What the project is doing

In the project's own words, from its summary on CORDIS.

SENSOPAD initiative heralds a transformative era in women's health by addressing the longstanding challenges posed by Endometriosis (ED). ED's early detection is often underdiagnosed due to its asymptomatic nature, pivotal for improved health outcomes and reduced healthcare costs. SENSOPAD introduces two pioneering ED sensing systems: sensoPAD, seamlessly integrated into sanitary pads, and sensoMFgFET, a portable Point-of-Care (POC) device.

SensoPAD comprises three Biological Processing Units (BPU) - BPU-1, BPU-2, and BPU-3 - ensuring continuous monitoring. BPU-1 combines an electrochemical sensor with RFID, while BPU-2 merges a chemical-based fuel cell with an electrochromic cell. BPU-3, an energetically autonomous unit, synergizes BPU-1 and BPU-2 capabilities for seamless monitoring. SensoMFgFET, a POC device, utilizes microfluidic systems and bio-conjugated gFET with RFID functionality, capturing specific DNA SNPs from the menstrual fluid as early ED indicators.

Both devices are complemented by a user-friendly mobile application enabling real-time data acquisition and analysis. An advanced cloud platform integrated with AI enhances diagnostic accuracy. This innovative approach shifts the paradigm in ED detection, empowering women, clinicians, and healthcare systems. SensoPAD detects biomarkers, providing insights during menstrual cycles. If concerns arise during its use, users transition to sensoMFgFET at clinical points, combining at-home convenience with clinical precision.

SENSOPAD aims to reduce ED diagnosis time from eight years to days, enabling early treatment, preventing symptom deterioration, optimizing infertility care, and streamlining healthcare journeys. Integrating SENSOPADs with a mobile app and AI-enriched cloud platform ensures accurate, cost-effective diagnostics, detecting silent instances of ED, and signifies a paradigm shift, fostering informed, proactive, and inclusive healthcare decisions for women worldwide.

Topics

Who is involved

OrganisationCityCountryRole
Ethnicon Metsovion PolytechnionAthinaGreeceCoordinator
Innovation in Research & Engineering SolutionsBruxelles / BrusselBelgiumParticipant
White Research SRLSint-GillisBelgiumParticipant
Signalgenerix LimitedLimassolCyprusParticipant
Copenhagen Business SchoolFrederiksbergDenmarkParticipant
Biog3d Monoprosopi I.k.e.PeiraiasGreeceParticipant
Graphenea Semiconductor SLDonostiaSpainParticipant
Universidade Da CorunaLa CorunaSpainParticipant
Gals Bio LtdMevaseret ZionIsraelParticipant
Alma Mater Studiorum - Universita Di BolognaBolognaItalyParticipant
International Iberian Nanotechnology LaboratoryBragaPortugalParticipant
Universidade De CoimbraCoimbraPortugalParticipant
Freda Health Products LtdLondonUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI